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We conducted a randomized trial designed to calculate
human in vivo immune protection factors of two
sunscreen preparations in a model of ultraviolet-
induced local suppression of the induction of contact
hypersensitivity to 2,4-dinitrochlorobenzene. Seventy-
¢ve male subjects were exposed in a multistage study
to multiples of their individual minimal erythema dose
of solar-simulated ultraviolet radiation with or without
protection by an ultraviolet B sunscreen (sun protection
factor 5.2) or a broad-spectrum ultraviolet AþB sun-
screen (sun protection factor 6.2). After 24 h subjects
were sensitized with 50 lL of 0.0625% 2,4-dinitrochlor-
obenzene on a nonirradiated or ultraviolet-irradiated
¢eld on the buttock that was unprotected or protected
by sunscreen. Three weeks after sensitization the sub-
jects were challenged with varying concentrations of
2,4-dinitrochlorobenzene on their upper inner arm,
and the contact hypersensitivity response was deter-
mined at 48 and 72 h based on a semiquantitative clini-
cal score, contact hypersensitivity lesion diameters, and
dermal skin edema measurement by 20 MHz ultra-
sound. The 50% immunosuppressive dose ranged from
0.63 to 0.79 minimal erythema dose, depending on the
endpoint parameter. Both sunscreens o¡ered signi¢cant
immunoprotection (p¼ 0.014 ^ 0.002) and their immune
protection factor ranged from 4.5 to 5.8 (ultraviolet B
sunscreen) and from 7.7 to 11 (ultraviolet AþB sun-
screen).The immune protection factor of the ultraviolet
B sunscreen was similar to the sun protection factor
(5.2), whereas the sunscreen with broad-spectrum ultra-
violet AþB protection exhibited better immunopro-
tective capacity than predicted from the sun protection
factor. Key words: immune suppression/skin cancer/solar simu-
lated UV radiation/suberythemal e¡ect/sun protection factor.
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E
xposure of the skin to ultraviolet (UV) radiation in-
duces various biologic alterations, including local and
systemic immune suppression (Krutmann and El-
mets, 1995; Duthie et al, 1999). There is evidence that
UV-induced immune suppression is a signi¢cant fac-
tor in skin cancer formation, not only in experimental animals
(Kripke and Fisher, 1976; Streilein et al, 1994) but also in human
subjects (Yoshikawa et al, 1990). For instance, patients with a his-
tory of nonmelanoma skin cancer such as basal cell and/or squa-
mous cell carcinoma have been shown to be much more
susceptible than normal, healthy control subjects to UV-induced
immunosuppression as measured in the model of UV-induced
local suppression of the induction of contact hypersensitivity
(CHS) to a contact allergen (Yoshikawa et al, 1990). The signi¢-
cance of an intact immune system is particularly highlighted by
the well-known observation that therapeutically immunosup-
pressed organ transplant recipients have an increased risk of squa-
mous cell carcinoma at sun-exposed body sites (Boyle et al, 1984).
Moreover, there is evidence that UV-induced immunologic al-
terations may be involved in the formation of cutaneous melano-
ma (Donawho andWolf, 1996).
Skin cancer has become a major health problem; for example,
the American Cancer Society has estimated that in the USA alone
there might have been approximately 1.3 million cases of skin
cancer (including nonmelanoma skin cancer and melanoma) in
the year 2000, placing the incidence of skin cancer ahead of that
of all other malignancies (Moodycli¡e et al, 2000). Because expo-
sure to UV radiation from sunlight seems to be the major reason
for the enormous incidence of skin cancer (Urbach, 1997), cancer
prevention strategies have focused on the reduction of environ-
mental UV exposure by a broad range of di¡erent measures, in-
cluding the administration of sunscreens.
The designated e⁄cacy of sunscreens is indicated by the sun
protection factor (SPF), which is solely based on ability to pre-
vent erythema. Signi¢cant improvements in the development of
sunscreens have led to preparations with SPF ratings of 30 and
higher. Sunscreens are highly protective against sunburn but the
e⁄cacy in protecting against nonerythema endpoints is not well
understood (Donawho andWolf, 1996). In animal studies, sunsc-
reens protected against chronic UV-induced skin aging, tumor
initiation, and tumor promotion (for review see Donawho and
Wolf, 1996). There is some evidence that sunscreens protect hu-
man subjects from the formation of squamous cell (but not basal
cell) carcinoma (Green et al, 1999) and from the formation of ac-
tinic keratoses, lesions that may be precursors to squamous cell
carcinoma (Thompson et al, 1993; Naylor et al, 1995). There is in-
conclusive evidence concerning the bene¢t of sunscreens in the
prevention of cutaneous melanoma, the most dangerous and po-
tentially lethal form of skin cancer. The results of several retro-
spective epidemiologic studies have suggested that the use of
sunscreens may even be associated with an increased melanoma
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risk, after statistical adjustment of phenotypic and sun exposure-
related factors (for review see Donawho and Wolf, 1996; Wein-
stock, 1999). A possible explanation for these results is that sun-
screens may provide insu⁄cient immunoprotection to be e¡ective
in skin cancer prevention. Indeed, the ability of sunscreens to
protect laboratory animals and humans against the immunosup-
pressive e¡ects of UV radiation has been the subject of great con-
troversy (for review see Granstein, 1995; Wolf and Kripke, 1997;
Ullrich et al, 1999). It has been suggested that insu⁄cient sunsc-
reen protection from immunosuppression may increase the skin
cancer risk of consumers, particularly when high SPF sunscreens
are used to prolong sun exposure extensively (Wolf et al, 1994).
The labeled SPF on a sunscreen product approved for market is
determined in UVdose^response studies in humans, according to
de¢ned regulations (COLIPA, 1994; FDA, 1999). There is no simi-
lar requirement for assessing the immunoprotective capacity of
sunscreens; a very high number of subjects would be necessary
for such studies.
In this study, we used a CHS model to investigate the immu-
noprotective capacity of a sunscreen preparation containing a che-
mical UVB ¢lter and of a broad-spectrum sunscreen preparation
containing the same UVB ¢lter and an additional chemical UVA
¢lter. The purpose of the study was to assess the sunscreens in
terms of their immune protection factors (IPF) and to compare
IPF with conventional SPF. Sunscreen preparations were assessed
in terms of IPF for a speci¢c form of immunosuppression, deter-
mined in the commonly used human model of UV-induced local
suppression of the induction of CHS to the contact allergen dini-
trochlorobenzene (DNCB) (Kelly et al, 2000). We used a three-
stage study design in which data were analyzed after each stage
and used to determine appropriate UV light doses in the next
stage. The results of the study are particularly signi¢cant because
the susceptibility to this speci¢c form of UV-induced immuno-
suppression has been previously linked to skin cancer history
(Yoshikawa et al, 1990).
MATERIALS AND METHODS
Study design The studies consisted of a small study in healthy
volunteers to determine the SPF of sunscreen preparations and a larger,
randomized, 4 wk study in healthy volunteers, designed to evaluate IPF
of the sunscreen preparations, both conducted between November 1998
and April 2000 at the Photodermatology Department of the Department
of Dermatology, University of Graz, Austria. The studies were conducted
during periods of the year with low environmental sunlight radiation
(November to April) to minimize interference with the arti¢cial UV
exposure given in the study. Inclusion criteria were as follows: age
between 18 and 60 y, general good health status, skin phototype II to IV,
and absence of skin cancer at study entry. Exclusion criteria were
pregnancy, lactation, childbearing potential in the absence of a reliable
contraceptive method, psychiatric disease, seizure disorders and/or
compromised central nervous system function, congenital or acquired
immunode¢ciency syndrome, genetic disease with DNA repair de¢ciency
(e.g., xeroderma pigmentosum), porphyria, serious infection within the
previous 28 d, Karnofsky index less than 80, administration of an
investigational new drug or immunosuppressive medication within the
last 6 mo before study entry (IPF study only), taking an anti-
in£ammatory or photosensitizing medication, previous contact with
DNCB (IPF study only), skin disease or other disease that might interfere
with sensitization and/or CHS to DNCB (IPF study only), and high
amounts of total body exposure or direct exposure of the test sites on the
buttocks and upper arm to environmental and/or arti¢cial UV radiation
during the last 4 wk prior to study entry. The study protocols were
approved by the local ethics committee, and all subjects provided
informed consent before participation.
Di¡erent groups of volunteers were enrolled in the SPF study and the
IPF study. The SPF study included sunscreen application and exposure to
a series of UVdoses on day 1 and reading of the UVerythema response on
day 2 (as described below for determination of the sunscreen SPF).The IPF
study included a screening visit and study visits on days 1, 2, 4, 22, 24, and
25. At the screening, the individual minimal erythema dose (MED) of
solar-simulated radiation was determined for each subject (as described
below for determination of the sunscreen SPF).
Patients were enrolled in three sequential study stages, with enrollment
in each stage delayed until data analysis from the previous stage was
complete. There were three di¡erent treatment groups: group A (no
sunscreen), group B (UVB sunscreen no. 321), and group C (UVAþB
sunscreen no. 322) for the di¡erent study stages. All subjects in stage I
were in group A and were randomly assigned to a UV irradiation
treatment cohort for the CHS assay. Subjects in stages II and III were
randomly assigned both to treatment group (group A, group B, or group
C) and to UV irradiation treatment cohort for the CHS assay, using a
randomization procedure. UV irradiation treatment cohorts for the CHS
assay received no irradiation (control group) or one of four UV dose
levels. UV doses in stage I were chosen on a regular UV dosage grid. In
stages II and III the grid was decreased in order to place the UV doses
within the con¢dence interval (CI) of the location parameter of the
logistic function, as described below.
If used, a sunscreen was applied 20 min before UV exposure at a
concentration of 2 mg per cm2. Subjects received a single exposure to
solar-simulated UV radiation in a previously unexposed, 5  5 cm ¢eld
on the left buttock (with or without prior sunscreen treatment) on day 1.
In stage I subjects (all in group A) were exposed to UV irradiation on the
designated 5  5 cm area of the buttocks at single doses equivalent to 0,
0.5, 1, 2, or 3  the individual MED; in stage II, at single doses equivalent
to 0, 0.5, 0.75, 1, or 1.5  the individual MED; and in stage III, at single
doses equivalent to 0, 0.75, 1, 1.25, or 1.5  the individual MED. In stages
II and III sunscreen-treated subjects in groups B and C received the same
relative range of UV doses but the UV doses were multiplied by the
speci¢c SPF of the sunscreen (5.2 and 6.2 for subjects in groups B and C,
respectively; see Results below). Twenty-four hours after UV irradiation
(day 2), volunteers were sensitized on unirradiated or UV-irradiated,
sunscreen-protected or unprotected buttock skin with DNCB, as
previously described (Kelly et al, 2000). Twenty-one days after sensi-
tization (day 22), the subjects were challenged with DNCB for deter-
mination in a CHS assay, described below.
UVradiation source UV-simulated radiation was provided by an Oriel
1000 W solar simulator (Oriel Corp., Darmstadt, Germany) equipped with
a dichroic mirror, an atmospheric attenuation ¢lter (WG320/1 mm), and a
UG5/1 mm visible infrared light bandpass blocking ¢lter. Irradiance was
routinely measured and monitored by a wide-band thermopile radiometer
(Dexter Research 2M model with quartz window) (Medical Physics,
Dryburn Hospital, Durham, UK), calibrated by the Regional Medical
Physics Department, Royal Victoria In¢rmary Unit (Newcastle upon
Tyne, UK), using a reference thermopile (Hilgar-Swartz FT17). The total
irradiance at 20 cm from the outermost ¢lter of the system was 12.0 mW
per cm2, as measured by the wide-band Dexter Research thermo-
pile radiometer. During the study, this UV irradiance of the Oriel
solar simulator was kept constant by use of an integrated automated
photo feedback system. The spectrum of the light source conformed
to FDA and COLIPA (ComiteŁ de Liaison des Associations Euro-
peŁ enes de l’Industrie de la Parfumerie, des Produits Cosmetiques et de
Toilette) regulations for sunscreen testing, as determined by an Internatio-
nal Light spectroradiometer system (International Light Inc., Newburyport,
Massachusetts).
Sunscreen preparations Proprietary sunscreen preparations were
provided for this study by Beiersdorf AG (Hamburg, Germany). A
preparation designated as UVB sunscreen no. 321 contained 4% of the
chemical UVB ¢lter methylbenzylidine camphor, and a preparation
designated as broad-spectrum UVAþB sunscreen no. 322 contained 4%
methylbenzylidine camphor and 1.5% butyl methoxy dibenzoylmethane,
a chemical UVA ¢lter. The same oil-in-water emulsion (containing stearic
acid, glyceryl stearate, octyldodecanol, dicaprylyl ether, cetearyl alcohol,
phenoxyethanol, methylparaben, ethylparaben, propylparaben, butylpara-
ben, sodium hydroxide, glycerin, trisodium ethylenediamine tetraacetic
acid, caprylic/capric triglyceride, and carbomer) was used as vehicle for
formulation of both sunscreens. The absorbance spectrum of the
sunscreen preparations is shown in Fig 1. The critical wavelength of the
UVB sunscreen no. 321 was 332 nm and that of the UVAþB sunscreen
no. 322 was 375 nm, according to the Di¡ey de¢nition (Di¡ey et al, 2000).
SPF determination Before starting the CHS studies, the mean SPF
of each sunscreen was determined, according to FDA and COLIPA
guidelines. Brie£y, healthy volunteers were UV irradiated with the Oriel
1000 W solar simulator in series of six 1  1 cm areas on unprotected or
sunscreen (2 mg per cm2)-protected buttocks with graded solar-simulated
UVdoses at 25% increments. Erythema was scored visually 24 h after UV
exposure and the MED was de¢ned as the lowest dose required to produce
perceptible erythema with a sharp border. The individual SPF of a
IPF OF CHEMICAL SUNSCREENS 1081VOL. 121, NO. 5 NOVEMBER 2003
sunscreen was determined in each subject by calculating the ratio of MED
with a sunscreen versusMED without a sunscreen.Then, a mean SPF value
and 95% CI were calculated for each sunscreen.
CHS assay For sensitization, DNCB (Sigma-Aldrich, St Louis,
Missouri) was applied using a 12 mm paper ¢lter disk, soaked with 50 mL
of 0.0625% DNCB in ethanol (31.25 mg per 50 mL). The ¢lter paper was
mounted inside a 12 mm aluminum Finn chamber (Epitest Ltd, Tuusula,
Finland) that was taped with hypoallergenic Scanpore (Epitest Ltd) tape
to an unirradiated site or to the 5  5 cm UV-irradiated site on the
buttocks for 48 h until removal on day 3. The DNCB concentration used
for epicutaneous application was previously found to be su⁄cient to
sensitize human subjects (Friedmann, 1994; Kelly et al, 1998, 2000).
An average prechallenge skin thickness was calculated for each study
participant; prestudy testing had revealed signi¢cant interindividual
di¡erences but no signi¢cant intraindividual di¡erences in the skin
thickness of the upper inner arm in di¡erent subjects (data not shown). On
day 22, the average prechallenge dermal skin thickness of the challenge area
on the arm was determined by ultrasound measurements made at three
randomly selected sites in the challenge area, immediately before
application of the patch apparatus (see below). Subjects were then
challenged on the upper inner arm by the application of a patch with a
series of 5 8 mm Finn chambers, each containing an 8 mm paper ¢lter
disk (Epitest) that was moistened with a 20 mL solution of DNCB in
ethanol. The ¢ve Finn chambers were arranged to have increasing amounts
of DNCB, from 0, 3.125, 6.25, 12.5, to 25.0 mg DNCB. Before taping the
patch apparatus in place, CHS elicitation sites were marked by putting
slight pressure on the patch apparatus positioned at the exact application
site, in order to recognize the imprints of the Finn chambers, and then
marking the site of each chamber of the patch apparatus with a surgical
marker pen. The patch was taped and left in place on the arm for 48 h. At
49 h after challenge (1 h after removal of the patch) and at 72 h after
challenge, CHS responses at the ¢ve challenge sites were quanti¢ed by
means of: (1) a clinical score (0, no reaction; 0.5, macular erythema; 1,
erythema and edema; 2, papules and small blisters; 3, bulla or erosion or
spreading reaction); (2) measurement of the lesion diameter in millimeters;
and (3) measurement of skin swelling using 20 MHz ultrasound
(Dermascan C, Cortex Technology, Hadsund, Denmark). The ultrasound
measurements were performed using ultrasonic coupling gel, and a
scanning image of each elicitation site was recorded. The mean dermal
skin thickness of a challenge site was obtained from measurements at three
randomly selected locations along the horizontal length of a ultrasound
scanning image. The increase of dermal skin thickness after challenge (i.e.,
dermal skin swelling) was calculated for each elicitation site by subtracting
the average dermal skin thickness before CHS challenge (obtained by
measurements at the three randomly selected prechallenge locations) from
the mean dermal skin thickness after challenge.
Statistical model and data analysis The CHS responses (endpoints)
were dermal skin thickness, clinical score, and the CHS lesion diameter.
For statistical analysis, the data of the 49 and 72 h postchallenge readings
from the ¢ve di¡erent DNCB challenge sites of each of the endpoints (i.e.,
dermal skin thickness, clinical score, and the CHS lesion diameter) were
pooled for each subject and a mean response value was calculated for each
endpoint for each subject (Matthews et al, 1990). The relationship between
UV radiation dose and mean CHS response was modeled by a four-
parameter logistic model for the logarithm of dose. The model formula is
as follows:
mðDÞ ¼ ðc dÞ  invlogit

logðDÞ  a
b

þ d
where m is prediction of immune reaction, D is the UV dose, invlogit(x) is
ex/(exþ1), a is 50% immunosuppressive UV dose (ID50), b is slope, c is
maximal immune suppression, and d is minimal immune reaction. The
predicted values range from minimum response (d) to maximum response
(c). The slope of the logistic curve at the point of steepest descent is
inversely proportional to the slope parameter (b). The middle of the range
of predicted response values is obtained if the dose is equal to the ID50 (a).
The standard deviation of the CHS response (s) was modeled as dose
dependent, as follows:
sðmÞ ¼ s0ð1þ ymÞ
where s represents standard deviation of response, m represents prediction
of immune reaction, s0 and y represent parameters of the standard
deviation function of the immune reaction.
Each of the three experimental groups had a separate ID50 parameter (a),
whereas the remaining parameters were common to all groups. The model
parameters were calculated by the weighted least squares method (Carroll
and Ruppert, 1988). IPF was calculated by dividing the ID50 of a sunscreen-
treated group by the ID50 of the sunscreen-untreated group. Ninety-¢ve
percent CI and p-values were calculated by nonparametric bootstrap and
randomization tests (Efron and Tibshirani, 1993). A thousand replications
were performed in the simulations. Two-sided p-values less than 0.016
were considered signi¢cant after Bonferroni adjustment of the signi¢cant
p-value level for multiple endpoint testing.
RESULTS
SPF determination Eighteen Caucasian volunteers (nine men
and nine women; median age, 29 y; age range, 19^46 y; all of skin
phototype III) were enrolled for SPF sunscreen testing, according
to FDA and COLIPA guidelines. The SPF were determined to be
5.2 (95% CI, 4.6^5.7) for the UVB sunscreen no. 321 and 6.2 (95%
CI, 5.3^7.1) for the broad-spectrum UVAþB sunscreen no. 322,
respectively (p¼ 0.002; Student’s paired t test).
IPF determination Seventy-¢ve healthy, Caucasian men
(median age, 26 y; range, 19^57 y; Fitzpatrick skin phototype II,
seven; III, 66; and IV, two) and 15 Caucasian women (median age,
29 y; range, 18^47 y; skin phototype II, one; and III, 14) were
enrolled in the sunscreen CHS immunoprotection studies
(Table I). Two men dropped out in stage I of the study due to
personal reasons, and three men had to be withdrawn from the
study in stage III due to a technical defect of the photo feedback
system of the UV light source. No data from those ¢ve male
subjects were included in the statistical analysis.
Inclusion of female subjects was stopped after stage I, as
statistical data analysis had revealed £uctuating levels of the CHS
response (data not shown), presumably depending on the
menstrual cycle, in accordance with results observed by another
group of investigators.1 This decision was taken because the
status of the menstrual cycle as a variability factor would
have required enrollment of much higher numbers of female
subjects in order to obtain meaningful results on sunscreen
immunoprotection. No data from female subjects were included
in the ¢nal statistical analysis.
The results obtained in the immune function studies were
similar for the di¡erent endpoint parameters, including clinical
score, diameter of lesion, and 20 MHz ultrasound skin edema
measurements, based on both biologic MED and physical UV
Figure1. Absorbance spectrum of the sunscreens. Sunscreens were
applied to roughened quartz plates at 0.75 mg per cm2 and absorbance
was measured spectroradiometrically at 1 nm intervals. The values given
represent means from measurements performed at four di¡erent locations
on each of four quartz plates.
1Oberhelman et al: J Invest Dermatol 98:655, 1992 (Abstr.)
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dose. The raw data, linked mean values at the di¡erent UVdoses
applied (angular lines), and calculated logistic curves (S-shaped)
are shown in Fig 2. Overall, both the angular lines and
S-shaped logistic curves clearly show a similar shift to the right
for groups B and C, which received sunscreen treatment,
compared with group A, which did not, indicating that the
sunscreen preparations used in the study provided signi¢cant
immunoprotection. Importantly, the curves for the UVAþB
broad band sunscreen no. 322 showed the greatest shift to the
right, indicating that this preparation provided best protection
against immunosuppression, consistent with its higher SPF.
Table II shows the calculated ID50 values (from the statistical
model) for the di¡erent treatment groups and the calculated IPF
for the sunscreen preparations, based on the endpoint parameters
for both biologic MED and physical UVdose. Mean ID50 values
in group A (no sunscreen) ranged from 0.63 to 0.79 MED,
depending on the endpoint parameter, whereas mean ID50
values ranged from 3.3 to 3.9 MED and from 5.9 to 7.1 MED in
groups B (UVB sunscreen) and C (UVAþB sunscreen),
respectively, depending on the endpoint parameter (Table II).
The immunoprotection by the sunscreens was signi¢cant
(po0.014 to.002). The mean IPF of the UVB sunscreen no. 321
was calculated as the ID50 ratio of group B/group A and ranged
from 4.5 to 5.3. The mean IPF of the UVAþB sunscreen no. 322
(ID50 ratio of group C/group A) ranged from 7.7 to 9.8, based on
MED for the di¡erent endpoint parameters. Calculations based
on the physical UV dose applied (physical ID50) yielded slightly
higher IPF, with the mean IPF ranging from 4.9 to 5.8 and from
8.6 to 11 for group B (UVB sunscreen no. 321) and group C
(UVAþB sunscreen no. 322), respectively. IPF/SPF ratios were
calculated for each of the sunscreen preparations per endpoint.
For UVB sunscreen no. 321, the immunoprotective capacity was
in the range of the SPF, with the IPF/SPF ratio ranging from 0.88
to 1.0 based on MED and from 0.95 to 1.1 based on physical UV
dose. The IPF/SPF ratio for the UVAþB sunscreen ranged from
1.2 to 1.6 based on MED and from 1.4 to 1.8 based on physical
UV dose. A statistically signi¢cant di¡erence (po0.016 after
Bonferroni adjustment), however, was not present comparing
the IPF/SPF ratios of the UVB sunscreen no. 321 versus that of
the UVAþB sunscreen no. 322.
DISCUSSION
We determined the immunoprotective capacity of two sunscreen
preparations by calculating speci¢c IPF in humans using a meth-
od analogous to that used in standard SPF testing according to
FDA or European COLIPA guidelines. Using the common im-
munologic model of UV-induced local suppression of the induc-
tion of CHS to the contact allergen DNCB, the study showed
that both a UVB sunscreen and a UVAþB broad-spectrum
sunscreen (according to the requirements of the Di¡ey critical
wavelength de¢nition for broad-spectrum UV protection; Di¡ey
et al, 2000) exhibited signi¢cant immunoprotective capacity (Fig
2,Table II). The results were similar for all endpoints examined
(i.e., dermal skin swelling, lesion diameter, and clinical score),
based on both biologic MED and physical UV dose. For the
UVB sunscreen, the calculated IPF (4.5^5.8) approximately
equaled the SPF (5.2). Interestingly, however, the IPF calculated
for the UVAþB broad-spectrum sunscreen (7.7^11) were higher
than the SPF (6.2). The calculation of IPF/SPF ratios revealed that
the immunoprotective capacity of the UVAþB broad-spectrum
sunscreen exceeded the erythema protective capacity predicted
from its SPF by 20^80% depending on the endpoint (Table II);
however, the di¡erences did not reach statistical signi¢cance after
Bonferroni adjustment of the signi¢cant p-value level. Neverthe-
less, this result indirectly suggests that the UVA portion of
solar-simulated light may contribute to UV-induced immuno-
suppression more than to erythema and is consistent with the ob-
servation that exposure of UVA II (320^340 nm) can lead to the
suppression of CHS induction in humans (LeVee et al, 1997).
The observation that a broad-spectrum UVAþB sunscreen
may show greater immunoprotection against local suppression
of CHS induction is consistent with results of certain previous
immunoprotection studies in mice and humans. For instance,
Fourtanier et al (2000) compared in hairless albino mice two
sunscreens with the same SPF but di¡erent UV absorption prop-
erties and found that the sunscreen with the greater UVA protec-
tion gave higher protection against UV-induced systemic
suppression of CHS induction to the contact allergen dinitro-
£uorobenzene. Nghiem et al (2001) reported that UVA (320^400
nm) radiation was as e¡ective as solar-simulated UV radiation in
systemically suppressing the immunologic memory and estab-
lished immune response to Candida antigen in C3H mice. In
their study, a sunscreen containing only a UVB ¢lter had no pro-
tective e¡ect, whereas a sunscreen containing both UVA and
UVB ¢lters completely prevented UV-induced immunosuppres-
sion. Damian et al (1997) reported that broad-spectrum sunscreens
provided greater protection against UV-induced suppression of
CHS to nickel in sensitized human subjects, compared with a
UVB sunscreen. In another study by Moyal (1998), a broad-spec-
trumUVAþB sunscreen (but not a UVB sunscreen) reduced lo-
cal solar-simulated UV radiation-induced immunosuppression
and prevented its systemic e¡ect on the elicitation of delayed type
hypersensitivity to Multitest (Pasteur/MeŁ rieux) antigens in hu-
man volunteers.
The concept of IPF determination (analogous to conventional
SPF determination) was recently introduced to compare the im-
munoprotective capacity of sunscreens with their capacity to
protect from in£ammation; until now, the concept of IPF deter-
mination has been primarily used in experimental mice studies
(Wolf et al, 1993, 1994; Bestak et al, 1995; Roberts and Beasley,
1995; Roberts et al, 1996; Walker and Young, 1997). Damian et al
(1999), however, have recently determined in vivo human IPF by
measuring the UV-induced suppression of the CHS response to
nickel in nickel-allergic subjects and found a good correlation be-
tween SPF and IPF in their study, in which two broad-spectrum
sunscreens with SPF of 9 and 24 had an IPF of 6.5 and more than
Table I. Study disposition of subjectsa
Sequential
study stage Study time (from/to)
Erythematogenic
e¡ective UV
doses used in MEDb
Number and sex of subjects per UVdose
Total number and
sex of subjects per study
stage n¼ 90
Group A
(no sunscreen)
n¼ 50
Group B
(UVB sunscreen
#321) n¼ 20
Group C (UVAþB
sunscreen #322) n¼ 20
I February 1999 / April 1999 0, 0.5, 1, 2, 3 3 men and
3 women
none none 15 men and
15 women
II November 1999 / March 2000 0, 0.5, 0.75, 1, 1.5n 2 men 2 men 2 men 30 men
III March 2000 / April 2000 0, 0.75, 1, 1.25, 1.5n 2 men 2 men 2 men 30 men
aSubject numbers are based on intent-to-treat data. Two men in Stage I dropped-out due to personal reasons, and 3 men in Stage III had to be withdrawn due to a
technical defect of the light source.
bThe actual UVdoses applied in the sunscreen-treated groups were multiplied by the speci¢c SPF of the sunscreen used, i.e., 5.2 in group B and 6.2 in group C.
IPF OF CHEMICAL SUNSCREENS 1083VOL. 121, NO. 5 NOVEMBER 2003
Figure 2. Dose^response curves for the di¡erent endpoint parameters (edema, clinical score, and diameter) in relation to applied MED and
physical UV dose (J per cm2). Group A: sunscreen-untreated. Group B: treated with UVB sunscreen preparation no. 321. Group C: treated with UVAþ
B sunscreen no. 322. UV exposure doses applied in sunscreen treated groups B and C were multiples of the individual MED multiplied by the SPF of
preparation no. 321 (5.2) and no. 322 (6.2), respectively. The exact S-shaped curves represent the logistic curves generated by the four-parameter model
established for data analysis. The angular lines represent the linked mean values at the di¡erent UV doses applied. Note that there is a curve shift to the
right for the curves of sunscreen-treated groups B and C compared with the sunscreen-untreated group A for all endpoints based on both MED and total
physical UVdose applied, indicating that there was signi¢cant immunoprotection by both sunscreen preparations.
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25, respectively. The nickel model has the advantage that each
subject acts as his own control, allowing the use of smaller num-
bers of volunteers for immunoprotection studies, but the signi¢-
cance of the nickel model for UV-associated skin carcinogenesis is
unknown. A few previous studies have used the model of local
suppression of CHS induction to show that chemical sunscreens
can have immunoprotective capacity in humans; however, be-
cause ¢xed UV dosages were used and no UV dose^responses
were performed, IPF could not be determined in those studies
(Whitemore and Morison, 1995; Serre et al, 1997).
The results of this study con¢rm that the UV component of
sunlight can cause immunosuppression (as measured by local sup-
pression of CHS induction) in the absence of erythema in hu-
mans (Kelly et al, 1998, 2000). In this study, the ID50, i.e., that
dose at which the immune response was suppressed by 50%, ran-
ged between 0.63 and 0.79 MED, and the e¡ect reached its max-
imum at a dose as low as approximately 1.5 to 2 MED. At noon
on a summer day with a cloudless sky, an untanned individual of
medium skin color in central Europe or at a similar latitude in
North America could receive this substantial, immunosuppressive
dose from natural sunlight in approximately 10 to 20 min. This
comparison highlights the clinical signi¢cance of UV-induced
immunosuppression and its potential consequences in UV-asso-
ciated skin carcinogenesis.
The speci¢c immunologic model that we used is particularly
important because it shares mechanisms of immunologic altera-
tions with models of UV-associated skin carcinogenesis (Noonan
et al, 1981). For instance, the formation of transferable T suppressor
cells is a crucial event in both UV-induced local and systemic sup-
pression of the induction of CHS to a contact allergen (Toews et al,
1980) and in systemic abrogation of skin cancer immunity, at least
in rodents (Daynes and Spellman, 1977; Fisher and Kripke, 1978,
1982; Noonan et al, 1981; Ullrich and Kripke, 1984; Moodycli¡e
et al, 2000). Notably, occurrence of similar UV-induced alterations
of T cell populations has also been demonstrated in humans
(Duthie et al, 1999). Moreover, exposure of skin to UV radiation
leads to the production and release of immunosuppressive cyto-
kines such as tumor necrosis factor-a and interleukin-10 (Wolf
et al, 2000). These cytokines may play a part in local and systemic
suppression of the CHS response to contact allergens and may also
be involved in UV-caused skin carcinogenesis (Yarosh, 1992).
Knowing the protection factor of a sunscreen based on any type
of nonerythema biologic endpoint (Young andWalker, 1999), such
as a speci¢c form of immunosuppression, would be important,
particularly if the endpoint is critical for the prevention of a clini-
cal outcome such as skin cancer formation. Clearly, the determina-
tion of skin cancer protection factors of sunscreens would be
ultimately desirable; however, such studies have not been done un-
til now in experimental animals and cannot ethically be performed
directly in humans. Little is known at present about the immuno-
protective value of physical sunblocking agents such as titanium
dioxide or zinc oxide (Bestak et al, 1995; Van der Molen et al,
1998), which in recent years have been more and more commonly
used in commercial sunscreen preparations. In evaluating more
than the conventional SPF, this study represents a milestone in as-
sessing the protective capacity of sunscreens against a potentially
deleterious form of UV-induced local immune suppression that
has a relationship to skin cancer susceptibility (Yoshikawa et al,
1990). More work is now necessary to examine other speci¢c
forms of immunosuppression (using other available models),
which may also play a part in skin cancer formation.
This work was supported by research grant contract SMT4-CT 97-2152 from the
European Community.The sunscreens were kindly provided by Beiersdorf AG (Ham-
burg, Germany).We wish to thank V.Wendel and H. Gers-Barlag (Beiersdorf) for
their help and advice in establishing the clinical SPF testing procedure at our clinic
and providing the absorbance spectra of the sunscreens.We also like to thank D.A.
Kelly, S.L.Walker, J.M. Sheehan, and A.R.Young (Department of Environmental
Table II. ID50 doses and IPF, and IPF/SPF ratios for the UVB and UVAþB sunscreen preparations based on edema, clinical score,
and lesion diameter in the CHS model, by treatment group
Study Endpoint Measure Sunscreen (Group)
Measurements and Statistical Signi¢cance
ID50a (95% CI) IPFb (95% CI) IPF/SPFc (95% CI)
None (A) 0.79 (0.45 ^ 1.1) N/A N/A
MED UVB (B) 3.9 (2.0 ^ 5.1)e 5.0 (2.9 ^ 7.4) 0.97 (0.60 ^ 1.5)
Edema UVA þ B (C) 6.1 (3.3 ^ 8.9)e 7.7 (5.0 ^ 14) 1.2 (0.83 ^ 2.1)
UV Dosed (J/cm2) None (A) 3.4 (2.1 ^ 5.4) N/A N/A
UVB (B) 19 (9.6 ^ 28)e 5.5 (3.0 ^ 8.5) 1.1 (0.62 ^ 1.7)
UVA þ B (C) 29 (18 ^ 46)e 8.6 (5.3 ^ 15) 1.4 (0.82 ^ 2.2)
Clinical Score MED None (A) 0.63 (0.23 ^ 0.90) N/A N/A
UVB (B) 3.3 (1.4 ^ 5.0)f 5.3 (2.9 ^ 10) 1.0 (0.55 ^ 2.0)
UVA þ B (C) 5.9 (3.9 ^ 8.1)e 9.4 (6.4 ^ 23)i 1.5 (0.98 ^ 3.7)
UV Dosed (J/cm2) None (A) 2.9 (2.0 ^ 4.0) N/A N/A
UVB (B) 17 (8.8 ^ 24)g 5.8 (3.3 ^ 8.9) 1.1 (0.61 ^ 1.7)
UVA þ B (C) 30 (22 ^ 39)e 10 (7.1 ^ 15)j 1.7 (1.1 ^ 2.4)
Lesion Diameter MED None (A) 0.73 (0.10 ^ 1.2) N/A N/A
UVB (B) 3.3 (0.67 ^ 5.4)h 4.5 (1.8 ^ 12) 0.88 (0.37 ^ 2.1)
UVA þ B (C) 7.1 (4.2 ^ 26)e 9.8 (5.1 ^ 144)i 1.6 (0.50 ^ 8.1)
UV Dosed(J/cm2) None (A) 3.2 (1.8 ^ 5.1) N/A N/A
UVB (B) 16 (6.0 ^ 28)f 4.9 (1.9 ^ 10) 0.95 (0.39 ^ 1.9)
UVA þ B (C) 35 (24 ^ 59)e 11 (6.6 ^ 25)i 1.8 (1.0 ^ 4.7)
The signi¢cance level was po0.016 after Bonferroni adjustment for multiple endpoint testing. N/A, not applicable.
aID50 (95% con¢dence intervals), ID50 dose as calculated from the statistical model (see Materials and Methods).
bIPF (95% con¢dence intervals), IPF of a sunscreen as calculated by dividing the computed ID50 of the group treated with UVB sunscreen #321 (Group B) or the
group treated with UVAþB sunscreen #322 (Group C), respectively, by the ID50 of the sunscreen-untreated group (Group A).
cIPF/SPF (95% con¢dence intervals) ratio as calculated by dividing the IPF of a sunscreen by its SPF. IPF/SPF valueo 1, immunoprotection smaller than expected; IPF/
SPF value 4 1, immunoprotection greater than expected from the SPF of a sunscreen.
dUV exposure doses applied in the sunscreen-treated groups were multiples of the indiviudal MED multiplied by the SPF of the UVB preparation (5.2) and the
UVAþB preparation (6.2), respectively.
ep¼ 0.002; fp¼ 0.007; gp¼ 0.005; hp¼ 0.014 for comparison of ID50 of sunscreen group vs. no sunscreen group.
ip¼ 0.014; jp¼ 0.005 for comparison of IPF of UVB
sunscreen #321 vs. UVAþB sunscreen #322.
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Dermatology, StJohn’s Institute of Dermatology, Guy’s King’s College and StThomas
School of Medicine, King’s College London, St.Thomas Hospital, London, U.K.) for
their advice in establishing clinical procedures of the immune function study, C. Mazi-
lier for providing a reference transmission spectrum of the sunscreens, A. Fourtanier for
critical reading of the manuscript and B.J. Rutledge for editing assistance. We also
would like to thank all the volunteers for participating in this study.
Note added at acceptance of manuscript: Kelly et al (2003) re-
cently reported from a study in UK on the e¡ect of a commercial
UVB sunscreen with an SPF of 15 in the very same human model
of UV-induced local suppression of CHS that we used in our
study. They found that the capacity for immunoprotection of
their sunscreen was less than half of that for erythema.The reason
for this di¡erence to our study remains unclear at present; how-
ever, di¡erences in the study populations may account for. In the
UK study there was a predominance of women and all study par-
ticipants were of skin phototype I/II. In contrast, in our sunscreen
immunoprotection study only men were enrolled and the major-
ity of them were of skin phototype III, being the most common
skin phototype in Austria. Indeed, a previous study from the UK
has shown that at a given level of sunburn subjects of skin photo-
type I/II are much more sensitive to UV-induced immune sup-
pression than subjects of skin phototype III/IV (Kelly et al,
2000), which may result in a di¡erent IPF of a sunscreen as com-
pared with its SPF, depending on skin phototype.
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